CY1109407T1 - Υδατικο φαρμακευτικο παρασκευασμα που περιλαμβανει ροφλουμιλαστη - Google Patents

Υδατικο φαρμακευτικο παρασκευασμα που περιλαμβανει ροφλουμιλαστη

Info

Publication number
CY1109407T1
CY1109407T1 CY20081101429T CY081101429T CY1109407T1 CY 1109407 T1 CY1109407 T1 CY 1109407T1 CY 20081101429 T CY20081101429 T CY 20081101429T CY 081101429 T CY081101429 T CY 081101429T CY 1109407 T1 CY1109407 T1 CY 1109407T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparation
aquatic
preparation including
roflumilast
including roflumilast
Prior art date
Application number
CY20081101429T
Other languages
English (en)
Inventor
Rudolf Linder
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of CY1109407T1 publication Critical patent/CY1109407T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Περιγράφεται υδατικό φαρμακευτικό παρασκεύασμα για χορήγηση ενός ελαφρώς διαλυτού PDE4 αναστολέα.
CY20081101429T 2004-09-22 2008-12-10 Υδατικο φαρμακευτικο παρασκευασμα που περιλαμβανει ροφλουμιλαστη CY1109407T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004046235A DE102004046235A1 (de) 2004-09-22 2004-09-22 Arzneimittelzubereitung
EP05794694A EP1796668B1 (en) 2004-09-22 2005-09-21 Aqueous pharmaceutical preparation comprising roflumilast

Publications (1)

Publication Number Publication Date
CY1109407T1 true CY1109407T1 (el) 2014-07-02

Family

ID=35447576

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101429T CY1109407T1 (el) 2004-09-22 2008-12-10 Υδατικο φαρμακευτικο παρασκευασμα που περιλαμβανει ροφλουμιλαστη

Country Status (17)

Country Link
US (1) US9205044B2 (el)
EP (1) EP1796668B1 (el)
JP (1) JP5044404B2 (el)
AT (1) ATE408405T1 (el)
AU (1) AU2005286476B2 (el)
CA (1) CA2580397C (el)
CY (1) CY1109407T1 (el)
DE (2) DE102004046235A1 (el)
DK (1) DK1796668T3 (el)
ES (1) ES2314718T3 (el)
HR (1) HRP20080640T3 (el)
ME (1) ME01050B (el)
PL (1) PL1796668T3 (el)
PT (1) PT1796668E (el)
RS (1) RS50641B (el)
SI (1) SI1796668T1 (el)
WO (1) WO2006032675A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
MX2011002688A (es) * 2008-09-12 2011-04-12 Critical Pharmaceuticals Ltd Mejoramientos en la absorcion de agentes terapeuticos a traves de las membranas mucosas o la piel.
CN102481270A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗肿瘤障碍的方法
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
EP2544663B1 (en) 2010-03-12 2018-01-03 Berg LLC Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
WO2012121988A2 (en) * 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
CN102793684B (zh) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 罗氟司特液体制剂及其制备方法
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
AU2014251045B2 (en) 2013-04-08 2019-06-13 Berg Llc Treatment of cancer using coenzyme Q10 combination therapies
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
SG10201907816RA (en) 2013-09-04 2019-09-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
CN105287366B (zh) * 2014-06-18 2018-02-16 张蕊 一种维生素k1注射液及其制备方法
WO2016063906A1 (ja) 2014-10-24 2016-04-28 久光製薬株式会社 プロドラッグ
EP3319608A4 (en) * 2015-07-07 2019-04-03 LifeRaft Biosciences, Inc. POLOXAMER 188 FORMULATIONS WITH REDUCED SODIUM AND METHOD OF USE
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
KR102117525B1 (ko) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물
CA3166300A1 (en) 2020-01-31 2021-08-05 David W. Osborne Topical roflumilast formulation having improved delivery and plasma half-life
US20230102590A1 (en) * 2020-02-03 2023-03-30 Senju Pharmaceutical Co., Ltd. Use of polyether compound
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
US20240108609A1 (en) 2022-09-15 2024-04-04 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0706513B1 (de) 1993-07-02 2002-05-15 Byk Gulden Lomberg Chemische Fabrik GmbH Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
WO1999056776A2 (en) * 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
SI1161239T1 (en) 1999-03-10 2005-06-30 Altana Pharma Ag 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
US20020193393A1 (en) * 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AU2003232828B2 (en) * 2002-05-28 2010-06-24 Takeda Gmbh Topically applicable pharmaceutical preparation
US20030235631A1 (en) * 2002-06-17 2003-12-25 Pfizer Inc. Combination treatment for depression and anxiety
US20040058950A1 (en) * 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10230769A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
EP2298810A3 (en) * 2002-07-19 2011-08-03 Abbott Biotechnology Ltd Treatment of TNF alpha related disorders

Also Published As

Publication number Publication date
PL1796668T3 (pl) 2009-02-27
AU2005286476B2 (en) 2011-11-10
US9205044B2 (en) 2015-12-08
EP1796668B1 (en) 2008-09-17
DE602005009848D1 (de) 2008-10-30
JP5044404B2 (ja) 2012-10-10
SI1796668T1 (sl) 2009-02-28
WO2006032675A1 (en) 2006-03-30
DK1796668T3 (da) 2009-02-02
ATE408405T1 (de) 2008-10-15
PT1796668E (pt) 2008-12-22
ES2314718T3 (es) 2009-03-16
EP1796668A1 (en) 2007-06-20
JP2008513416A (ja) 2008-05-01
RS50641B (sr) 2010-06-30
DE102004046235A1 (de) 2006-03-30
CA2580397C (en) 2013-07-30
ME01050B (me) 2012-10-20
HRP20080640T3 (en) 2009-01-31
AU2005286476A1 (en) 2006-03-30
CA2580397A1 (en) 2006-03-30
US20070259009A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
CY1109407T1 (el) Υδατικο φαρμακευτικο παρασκευασμα που περιλαμβανει ροφλουμιλαστη
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
JP2007504142A5 (ja) Ｈｉｖプロテアーゼ阻害薬固体分散物を含む固体薬物剤形
ATE518844T1 (de) Kaliumsalz eines hiv-integrase-inhibitors
DK1511481T3 (da) Ophthalmologisk anvendelse af roflumilast til behandling af øjensygdomme
MEP43508A (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
DK1641438T3 (da) Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel
DK1480679T3 (da) Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
RS54438B1 (en) PHARMACEUTICAL DOSAGE FORM CONTAINING 6`-FLUORO- (N-METHYL-OR N, N-DIMETHYL) - 4-PHENYL-4`, 9`-DIHYDRO-3`H-SPIRO [CYCLOHEXANE-1,1`-PIRANO [3,4, B] INDOL] -4-AMINE
GEP20115222B (en) New pharmaceutical compounds
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
NO20061088L (no) Protonpumpe inhibitor formuleringer og fremgangsmater for fremstilling og anvendelse av slike formuleringer
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
CR9058A (es) Derivados de indol como inhibidores de la adenilato ciclasa soluble
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства
ATE511837T1 (de) Wässrige arzneimittelformulierung von 4-ä((4- carboxybutyl)-ä2-ä(4-phenethyl-benzyl)oxyü- phenethylüamino)methylübenzoesäure
AR029091A1 (es) Uso de compuestos de 1-amino-5-fenilpentano-3-ol y/o 1-amino-6-fenilhexano-3-ol para la preparacion de un medicamento con efecto antagonista de n-metil-d-aspartato-(nmda)
ATE458721T1 (de) Iminosäurederivate als inhibitoren von matrix- metalloproteinasen
EA200702590A1 (ru) Ингибиторы растворимой аденилатциклазы
WO2005023223A3 (de) Oral zu applizierende darreichungsform für schwerlösliche saure und amphotere wirkstoffe
ATE355084T1 (de) Pharmazeutische zusammensetzungen von lavendustin
TR200402760A2 (tr) Pantoprazol sodyumun dayanıklı oral farmasötik formülasyonu.